Literature DB >> 12393713

Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts.

Laura L W Cooling1, De Sheng Zhang, Stanley J Naides, Theodore A W Koerner.   

Abstract

Glycosphingolipids (GSLs) are complex macromolecules on cell membranes that have been shown to play a role in neutrophil differentiation, activation, phagocytosis, and adhesion to both microorganisms and vascular endothelium. Because GSLs are often cryptic antigens on cell membranes, little is known regarding GSL expression in early myelopoiesis. To study the latter, myeloblasts were collected from patients with acute nonlymphocytic leukemia (ANLL) who required therapeutic leukocytopheresis for hyperleukocytosis. The neutral GSLs were isolated and identified by high-performance thin-layer chromatography (HPTLC), HPTLC immunostaining, gas chromatography, nuclear magnetic resonance, and fast atom bombardment-mass spectrometry. Like mature peripheral blood neutrophils, myeloblasts expressed glucosylceramide, lactosylceramide, and the neolacto-family GSLs, lactotriaosylceramide and neolactotetraosylceramide. Unlike neutrophils and chronic myeloid leukemia, most ANLL samples also expressed the globo-series GSLs, globotriaosylceramide and globotetraosylceramide. Globo GSL expression was strongly associated with a myeloblastic (ANLL M0-M2) and monoblastic phenotype (M5). A weak association was also noted with expression of either lymphoid (P <.10) or early hematopoietic markers (terminal deoxynucleotidyl transferase [TdT], CD34; P <.10). Globo-positive ANLL samples bound both shiga toxin and parvovirus B19 on HPTLC immunostaining. Based on these findings, we propose that neolacto and globo GSLs are expressed during early myeloid differentiation. Globotriaosylceramide expression on myeloblasts, and possibly myeloid stem cells, may have important implications for the use of shiga toxin as an ex vivo purging agent in autologous stem cell transplantation. Expression of globotetraosylceramide, the parvovirus B19 receptor, on myeloblasts may also explain the association between B19 infection, aplastic anemia, and chronic neutropenia of childhood.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393713     DOI: 10.1182/blood-2002-03-0718

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients.

Authors:  Zheng Wang; Lijun Wen; Xiao Ma; Zijun Chen; Yunhui Yu; Jian Zhu; Yanping Wang; Zhenming Liu; Haiyan Liu; Depei Wu; Dapeng Zhou; Yunsen Li
Journal:  Glycobiology       Date:  2012-03-11       Impact factor: 4.313

Review 2.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  Shiga toxin and its use in targeted cancer therapy and imaging.

Authors:  Nikolai Engedal; Tore Skotland; Maria L Torgersen; Kirsten Sandvig
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

Review 4.  The Role of Glycosphingolipids in Immune Cell Functions.

Authors:  Tao Zhang; Antonius A de Waard; Manfred Wuhrer; Robbert M Spaapen
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

5.  Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.

Authors:  Ana Valeria Meléndez; Rubí M-H Velasco Cárdenas; Simon Lagies; Juliane Strietz; Lina Siukstaite; Oliver S Thomas; Jana Tomisch; Wilfried Weber; Bernd Kammerer; Winfried Römer; Susana Minguet
Journal:  Cell Mol Life Sci       Date:  2022-09-12       Impact factor: 9.207

Review 6.  Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2020-06-04       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.